When should apixaban (Eliquis) be initiated after stopping a heparin infusion?

When to Start Eliquis After Stopping Heparin Drip

Start apixaban immediately at the time of the next scheduled heparin dose without any overlap or bridging period. This approach is supported by FDA labeling and multiple international guidelines, which consistently demonstrate that direct oral anticoagulants like apixaban have rapid onset of action (peak effect in 3-4 hours) and do not require parenteral bridging 1.

Practical Transition Protocol

The optimal transition strategy depends on your clinical context:

For Most Clinical Scenarios (VTE Treatment, Atrial Fibrillation)

• Stop the heparin infusion
• Give the first dose of apixaban at the time the next heparin dose would have been due 1
• No overlap period is needed
• No bridging with subcutaneous heparin is required

The FDA label explicitly states: "Discontinue the anticoagulant other than warfarin and begin taking ELIQUIS at the usual time of the next dose of the anticoagulant other than warfarin" 1. This straightforward approach applies to transitions from both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH).

Dosing Considerations Based on Indication

For acute VTE treatment:

• Start apixaban 10 mg twice daily for 7 days, then 5 mg twice daily 2, 1
• This high-dose lead-in is critical even after parenteral anticoagulation
• Recent evidence suggests the full 7-day lead-in period should be maintained despite prior heparin exposure, as shortened durations (4 days) were associated with increased bleeding (18.5% vs 5.1%, P=0.02) 3

For atrial fibrillation:

• Start apixaban 5 mg twice daily (or 2.5 mg twice daily if dose reduction criteria are met) 1
• No lead-in period required

For VTE prophylaxis post-surgery:

• Start apixaban 2.5 mg twice daily 1

Critical Timing Considerations

Post-Procedural Context

If transitioning after a procedure where heparin was used:

• Low bleeding risk procedures: Resume apixaban approximately 24 hours post-procedure when hemostasis is established 4, 5
• Moderate/high bleeding risk procedures: Resume apixaban 48-72 hours post-procedure 4, 5, 6
• The first therapeutic dose should be given 12 hours after the last prophylactic LMWH dose if bridging was used 5

Avoiding Overlap Complications

Important caveat: While immediate transition is standard, be aware that:

• Apixaban can interfere with heparin anti-Xa monitoring if any overlap occurs 7
• Residual apixaban levels can persist for 3+ days after discontinuation and may cause overestimation of UFH anti-Xa activity 7
• This is primarily a monitoring concern rather than a clinical safety issue

Special Populations

Renal impairment:

• Apixaban can be used in severe renal impairment (CrCl 15-29 mL/min) with dose adjustment 1
• For VTE treatment with CrCl 15-29 mL/min: Consider 10 mg twice daily for 7 days, then 5 mg twice daily (though data are limited)
• For atrial fibrillation with severe renal impairment: Use 2.5 mg twice daily if meeting dose reduction criteria 1

Patients on dialysis:

• Apixaban may be reasonable (2b recommendation) over warfarin in end-stage renal disease 8
• Multiple observational studies support safety in this population 9

Common Pitfalls to Avoid

1. Do NOT bridge with LMWH during the transition - This increases bleeding risk without reducing thrombotic events 5, 6

2. Do NOT delay apixaban initiation unnecessarily - The rapid onset means therapeutic anticoagulation is achieved within hours 1

3. Do NOT use warfarin-style bridging protocols - These are outdated for DOACs and increase bleeding complications 6

4. Do NOT skip the 7-day lead-in for VTE treatment - Even with prior parenteral anticoagulation, the full 10 mg twice daily for 7 days regimen should be completed 3

5. Do NOT overlap heparin and apixaban - Sequential therapy (stopping one, starting the other) is the correct approach 1

Monitoring

• No routine laboratory monitoring is required for apixaban 10
• Anti-Xa levels correlate with apixaban exposure but are not needed for routine management 11
• Monitor for clinical signs of bleeding or thrombosis
• Reassess renal function if clinical status changes, as this may require dose adjustment 5